Fundraising Fox
Grannus Therapeutics
Indianapolis, US · Founded 2020 · United States corporation · 2 known investors
Find your way into Grannus Therapeutics
Sign up to see every warm intro you have to Grannus Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Grannus Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Grannus Therapeutics develops Hsp90 inhibitors that selectively target the beta isoform of the Hsp90 protein for cancer treatment. Its lead candidate, GRE317, is designed for single-agent anti-tumor activity and combination with therapies such as PARP inhibitors and immunotherapies, with programs advancing toward IND-enabling milestones and clinical studies.
Founders & leadership
Grannus Therapeutics was founded in 2020 by Brian Blagg and Sanket Mishra.
Investors · 2
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$1.8M disclosed across 2 rounds · 2022–2023
▶$800KraisedJan 2024 · 9 investors · BiotechnologyRule 506(b)
- John FoglesongExecutive Officer, Director
- Brian BlaggDirector
- Offering amount
- $800K
- Amount sold
- $800K
- Minimum investment
- $250K
- First sale
- Nov 2023
- Incorporated
- Corporation, United States, 2020
- Federal exemptions
- 06b
▶$950KraisedJan 2022 · 11 investors · BiotechnologyRule 506(b)
- John FoglesongExecutive Officer, Director
- James ThompsonDirector
- Brian BlaggDirector
- Offering amount
- $1M
- Amount sold
- $950K
- Minimum investment
- $35K
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Companies working in the same space as Grannus Therapeutics.
Frequently asked questions
- What does Grannus Therapeutics do?
- Grannus Therapeutics develops Hsp90 inhibitors that selectively target the beta isoform of the Hsp90 protein for cancer treatment. Its lead candidate, GRE317, is designed for single-agent anti-tumor activity and combination with therapies such as PARP inhibitors and immunotherapies, with programs advancing toward IND-enabling milestones and clinical studies.
- Who founded Grannus Therapeutics?
- Grannus Therapeutics was founded by Brian Blagg, Sanket Mishra in 2020.
- Who are Grannus Therapeutics's investors?
- Grannus Therapeutics's investors include 1842, Elevate Ventures.
- How much funding has Grannus Therapeutics raised?
- Grannus Therapeutics has disclosed $1.8M raised across 2 rounds.
- Where is Grannus Therapeutics headquartered?
- Grannus Therapeutics is headquartered in Indianapolis, US.